NEW YORK, NY / ACCESSWIRE / June 9, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Canaan Inc. (NASDAQ:CAN)
CONTACT JAKUBOWITZ ABOUT CAN:
https://claimyourloss.com/securities/canaan-inc-loss-submission-form-2/?id=16744&from=1
Class Period : February 10, 2021 - April 9, 2021
Lead Plaintiff Deadline : June 14, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company’s next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan’s 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 (“4Q19”) sales and more than 93% quarter-over-quarter compared to its third quarter FY20 (“3Q20”) sales.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
CONTACT JAKUBOWITZ ABOUT ACAD:
https://claimyourloss.com/securities/acadia-pharmaceuticals-inc-loss-submission-form/?id=16744&from=1
Class Period : June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 18, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
PureCycle Technologies, Inc. (NASDAQ:PCT)
CONTACT JAKUBOWITZ ABOUT PCT:
https://claimyourloss.com/securities/purecycle-technologies-inc-loss-submission-form/?id=16744&from=1
Class Period : November 16, 2020 - May 5, 2021
Lead Plaintiff Deadline : July 12, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle’s financial projections are baseless; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law